|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300068228 |
|
最近更新日期: Date of Last Refreshed on: |
2023-02-10 15:42:34 |
|
注册时间: Date of Registration: |
2023-02-10 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
一项前瞻性单盲对照研究,L-shape胶原型脱矿无机牛骨与脱矿无机牛骨在前牙区水平向骨增量的临床效果对比 |
|
Public title: |
The clinical efficacy comparison between a L-shape collagen stabilized demineralized bovine bone mineral and demineralized bovine bone mineral in horizontal ridge augmentation in anterior region: a prospective, single-blinded, controlled randomized study. |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
一项前瞻性单盲对照研究,L-shape胶原型脱矿无机牛骨与脱矿无机牛骨在前牙区水平向骨增量的临床效果对比 |
|
Scientific title: |
The clinical efficacy comparison between a L-shape collagen stabilized demineralized bovine bone mineral and demineralized bovine bone mineral in horizontal ridge augmentation in anterior region: a prospective, single-blinded, controlled randomized study. |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
史芮雯 |
研究负责人: |
兰晶 |
|
Applicant: |
Ruiwen Shi |
Study leader: |
Jing Lan |
|
申请注册联系人电话: Applicant telephone: |
+86 15098775773 |
研究负责人电话: Study leader's telephone: |
+86 13964011826 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
srw19980625@163.com |
研究负责人电子邮件: Study leader's E-mail: |
kqlj@sdu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东大学,山东省济南市历下区文化西路44号 |
研究负责人通讯地址: |
山东大学,山东省济南市历下区文化西路44号 |
|
Applicant address: |
Shandong University, No. 44, West Culture Road, Lixia District, Jinan City, Shandong Province |
Study leader's address: |
Shandong University, No. 44, West Culture Road, Lixia District, Jinan City, Shandong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
山东大学 |
||
|
Applicant's institution: |
Shandong University |
||
|
研究负责人所在单位: |
山东大学/ 山东大学口腔医院 |
||
|
Affiliation of the Leader: |
Shandong University/ School and Hospital of Stomatology, Shandong University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
20230101 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
山东大学口腔医院伦理委员会 |
||
|
Name of the ethic committee: |
the ethic committee of School and Hospital of Stomatology, Shandong University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-01-12 00:00:00 |
||
|
伦理委员会联系人: |
吕爱芹 |
||
|
Contact Name of the ethic committee: |
Aiqin Lv |
||
|
伦理委员会联系地址: |
山东省济南市历下区文化西路44-1号 |
||
|
Contact Address of the ethic committee: |
No. 44-1, West Culture Road, Lixia District, Jinan City, Shandong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
山东大学口腔医院 |
||||||||||||||||||||||
|
Primary sponsor: |
School and Hospital of Stomatology, Shandong University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省济南市历下区文化西路44-1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 44-1, West Culture Road, Lixia District, Jinan City, Shandong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
瑞士盖氏制药有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Geistlich Pharma AG |
||||||||||||||||||||||
|
Target disease: |
horizontal bone defect in the anterior region (Class IV by Cawood-Howell, Type 1/4 or Type 2/4 by Terheyden) |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究的目的是在临床上评价采用L形无机骨胶原联合胶原膜(Geistlich Bio-Gide?)的GBR与采用无机牛骨(Geistlich Bio-Oss?)联合胶原膜(Geistlich Bio-Gide?)的GBR在HT0(垂直于种植体肩台长轴的方向)水平骨增加量方面(术后6个月时通过锥形束计算机断层扫描测量)的差异。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study is aimed to clinically evaluate whether GBR with L-shape anorganic bone collagen in combination with a collagen membrane (Geistlich Bio-Gide?) differs from GBR with anorganic bovine bone (Geistlich Bio-Oss?) in combination with a collagen membrane (Geistlich Bio-Gide?) in terms of the amount of horizontal bone gain at HT0 (lines perpendicular to the implant's long axis at the implant shoulder) measured by cone-beam computed tomography (CBCT) at 6 months after surgery. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
正中牙槽嵴切开后,从牙槽嵴顶抬高全层黏骨膜瓣,轻轻清创骨缺损。然后根据生产商的说明,将种植体固定装置(Straumann BL,Straumann Implant)插入理想的义齿位置。试验组受试者将接受采用L形技术的GBR。 使用15号刀片将去蛋白牛骨矿物质C(Geistlich Bio-Oss?胶原,250?mg,Geistlic Pharma AG,Wolhusen,瑞士)适当修剪成L形,并直接应用于开裂缺损处,使软块的内表面与暴露的种植体固定装置的咬合面和颊侧面相匹配。 在颊侧和咬合侧,对种植体周围开裂缺损处进行增量,使缺损处周围的骨壁凸出至少1 mm。随后,使用双层可吸收的天然双层胶原膜(NBCM,Geistlich Bio-Gide? 13×25 mm,Geistlich Pharma AG)覆盖L形DBBM-C。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
After midcrestal incision, full-thickness mucoperiosteal flaps will be elevated from the alveolar crest, and osseous defects will be gently debrided. Then the implant fixture (Straumann BL, Straumann Implant) will be inserted in the ideal prosthetic position according to the manufacturer's instructions. Participants in the test group will undergo GBR with L-shape technology. Demineralized bovine bone mineral-C (Geistlich Bio-Oss? Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switzerland) will be appropriately trimmed to an L-shape with a #15 blade and applied directly to the dehiscence defect, fitting the inner surface of the soft block to the occlusal and buccal surfaces of the exposed implant fixture. Peri-implant dehiscence defects will be augmented to achieve a minimum of 1 mm over-contour for the bony wall surrounding the defect, both at the buccal and occlusal aspects. Subsequently, the L-shaped DBBM-C will be covered using a double layer of absorbable native bilayer collagen membrane (NBCM, Geistlich Bio- Gide? 13 × 25 mm, Geistlich Pharma AG). |
||||||||||||||||||||||
|
纳入标准: |
(1)年龄≥18岁 |
||||||||||||||||||||||
|
Inclusion criteria |
(1)Age≥18y |
||||||||||||||||||||||
|
排除标准: |
(1)患有心脑血管相关全身性疾病,不能耐受手术, |
||||||||||||||||||||||
|
Exclusion criteria: |
(1)With cardiovascular and cerebrovascular-related systemic diseases who cannot tolerate surgery, |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-02-01 00:00:00至 To 2025-08-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-02-15 00:00:00 至 To 2024-02-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机数字用于分组。基本概念为: 1)为入组临床试验的每例受试者生成相应的随机数字。 2)按从小到大(或从大到小)的随机数字排序。 3)根据每个治疗组预设的样本量,以随机数字顺序选择相应的样本量,并分配给不同的治疗组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random numbers are used for grouping. The basic idea is: 1) Generate a corresponding random number for each subject included in the clinical trial. 2) Sort by random numbers from small to large (or from large to small). 3) According to the preset sample size of each treatment group, select the correspond |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
在单盲研究中,研究者知道不同组别中使用的移植材料,但受试者不知道。 |
|
Blinding: |
In a single-blinded study, the investigators are aware of the graft materials used in the different groups, but the subjects are not. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2025年6月,ResMan (www.medresman.org) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
June,2025. ResMan (www.medresman.org) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
纸质的病例记录表、电子数据采集和管理系统(ResMan) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form and Electronic Data Capture(ResMan). |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |